The FDA apparently deems an uncontrolled study acceptable – five months after saying no.
ApexOnco Front Page
Recent articles
Could RO7851624, newly into clinical trials, be RG6735?
The battle intensifies as LY4170156 matches torvuta-S with activity in FRα <25% expresers.
After promising early data in head and neck, J&J plans a new phase 3, Origami-5.
Full data from Edge-Gastric are presented at ESMO.
The first TUB-040 data come just after Tubulis raised €308m.
Both are heralded as a new first-line standard of care, but Datroway seems to have the edge.
But the ESMO discussant recommends against widespread use in hormone-sensitive disease.